Aadi Bioscience, Inc.
AADI
$2.08
-$0.0407-1.92%
| Weiss Ratings | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.84 | |||
| Price History | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.90% | |||
| 30-Day Total Return | -6.87% | |||
| 60-Day Total Return | 3.76% | |||
| 90-Day Total Return | -18.41% | |||
| Year to Date Total Return | -6.87% | |||
| 1-Year Total Return | -76.17% | |||
| 2-Year Total Return | -87.69% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -80.47% | |||
| 52-Week Low % Change | 8.39% | |||
| Price | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $8.60 | |||
| 52-Week Low Price | $1.55 | |||
| 52-Week Low Price (Date) | Jan 17, 2024 | |||
| 52-Week High Price (Date) | May 23, 2023 | |||
| Valuation | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 45.18M | |||
| Enterprise Value | -62.40M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.44 | |||
| Earnings Per Share Growth | -10.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.04 | |||
| Price/Book (Q) | 0.43 | |||
| Enterprise Value/Revenue (TTM) | -2.72 | |||
| Price | $1.91 | |||
| Enterprise Value/EBITDA (TTM) | 0.92 | |||
| Enterprise Value/EBIT | 0.92 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 26.97M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 424-744-8055 | |||
| Address | 17383 Sunset Boulevard Pacific Palisades, CA 90272 | |||
| Website | aadibio.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -295.36% | |||
| Profit Margin | -270.03% | |||
| Management Effectiveness | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -28.40% | |||
| Return on Equity | -- | |||
| Income Statement | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 24.35M | |||
| Total Revenue (TTM) | 24.35M | |||
| Revenue Per Share | $0.90 | |||
| Gross Profit (TTM) | -15.28M | |||
| EBITDA (TTM) | -71.76M | |||
| EBIT (TTM) | -71.93M | |||
| Net Income (TTM) | -65.77M | |||
| Net Income Avl. to Common (TTM) | -65.77M | |||
| Total Revenue Growth (Q YOY) | 21.03% | |||
| Earnings Growth (Q YOY) | -16.93% | |||
| EPS Diluted (TTM) | -2.44 | |||
| EPS Diluted Growth (Q YOY) | -16.38% | |||
| Balance Sheet | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 108.85M | |||
| Cash Per Share (Q) | $4.04 | |||
| Total Current Assets (Q) | 124.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 105.20M | |||
| Current Ratio (Q) | 4.720 | |||
| Book Value Per Share (Q) | $4.28 | |||
| Total Assets (Q) | 132.42M | |||
| Total Current Liabilities (Q) | 26.40M | |||
| Total Debt (Q) | 1.27M | |||
| Total Liabilities (Q) | 27.23M | |||
| Total Common Equity (Q) | 105.20M | |||
| Cash Flow | AADI - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 83.21M | |||
| Cash from Financing (TTM) | 326.00K | |||
| Net Change in Cash (TTM) | 23.87M | |||
| Levered Free Cash Flow (TTM) | -37.70M | |||
| Cash from Operations (TTM) | -59.66M | |||
